Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Ascelia Pharma AB (publ)
  6. News
  7. Summary
    ACE   SE0010573113

ASCELIA PHARMA AB (PUBL)

(ACE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Ascelia Pharma : Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF«

09/21/2021 | 01:31am EST

Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has signed a clinical collaboration agreement with Taiho Oncology Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology’s LONSURF® (trifluridine and tipiracil) film-coated tablets for oral use. The combination of Oncoral and LONSURF is investigational at this time and not approved for use in gastric cancer or any other disease.

As part of the agreement, Taiho Oncology will supply LONSURF as well as provide scientific expertise for the study. Depending on the results, the collaboration may be extended for further development of the two agents. Ascelia Pharma retains full development and commercialization rights to Oncoral.

“This is an important agreement for Ascelia Pharma, which shows the potential for Oncoral to be a new treatment regimen for gastric cancer. We believe this investigational all-oral tablet combination has the potential to provide a significant treatment benefit to patients suffering from this very aggressive cancer form where there is a massive unmet medical need,” said Magnus Corfitzen, CEO of Ascelia Pharma.

Following an initial dose-escalation the Phase 2 study will be a randomized controlled multicenter study of Oncoral added to LONSURF compared to LONSURF alone. The primary endpoint will be progression-free survival, with secondary endpoints including response rate, overall survival, pharmacokinetics, safety, and tolerability.

The study is planned to start in H2 2021 and will include approximately 100 patients with metastatic gastric cancer. The initial portion of the planned global study will be conducted at hospitals and clinics in Europe.

© Modular Finance, source Nordic Press Releases

All news about ASCELIA PHARMA AB (PUBL)
2021Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial
AQ
2021Ascelia Pharma AB Receives FDA Acceptance of IND Application for Oncoral Clinical Trial
CI
2021Results from Orviglance comparison study to gadolinium presented at RSNA 2021
AQ
2021Ascelia Pharma AB Announces Results from Orviglance comparison study to gadolinium pres..
CI
2021Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB
AQ
2021QUARTERLY REPORT Q3 2021 : Oncoral – entering clinical collaboration
AQ
2021Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
2021ASCELIA PHARMA : Food Effect Study with Orviglance successfully completed
AQ
2021Ascelia Pharma AB Completes Food Effect Study with Orviglance Successfully
CI
2021ASCELIA PHARMA : Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the ..
AQ
More news
Financials
Sales 2021 - - -
Net income 2021 -126 M -13,5 M -13,5 M
Net cash 2021 252 M 27,1 M 27,1 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 833 M 89,6 M 89,5 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 12
Free-Float -
Chart ASCELIA PHARMA AB (PUBL)
Duration : Period :
Ascelia Pharma AB (publ) Technical Analysis Chart | ACE | SE0010573113 | MarketScreener
Technical analysis trends ASCELIA PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 24,75 SEK
Average target price 58,00 SEK
Spread / Average Target 134%
Managers and Directors
Magnus Olafsson Corfitzen Chief Executive Officer
Kristian Borbos Chief Financial Officer
Peter James Arthur Benson Chairman
Carl Bjartmar Chief Medical Officer
Bo Jesper Hansen Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ASCELIA PHARMA AB (PUBL)-17.09%90
MODERNA, INC.-38.07%63 777
LONZA GROUP AG-19.59%49 711
IQVIA HOLDINGS INC.-13.62%46 556
SEAGEN INC.-16.20%23 689
ICON PUBLIC LIMITED COMPANY-17.32%20 842